SecBot SecBot

AKTX

Akari Therapeutics Plc
Nasdaq· Pharmaceutical Preparations· Inc. X0· CIK 0001541157 Biotech & Drug Discovery
$7.63 −0.60 (−7.23%)
Oct 26 4:00 PM ET · prev $8.23
Market cap
$18.5M
Nano cap
Median target
$27.00
+254% · range $19.50–30.00
Next earnings
Nov 11
in 16 days · EPS est. −$2.38
1 year
−76.0%
from $31.76 · Oct 27
30 days
−22.2%
from $9.81
52-week range
$3.06–32.80
−77% from high · low May 12
Avg volume 20D
41.6K
Oct 12 spike 112.4K
Short interest
14.5K
≈0.6% of shares · +35.0%
Days to cover
1.0
at average volume
Insider net
+$2.2K
1 buyer · 0 sellers · 12 mo
Filing reports
10
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/3 ·Next Earnings date, Nov 11, 2026
Strongest NEUTRAL Akari Therapeutics is holding a general meeting on October 28, 2026, to seek shareholder approval to…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $2.2K. No open-market sales.

  • Short sellersBUILDING

    Short interest +35.0% to 14.5K shares. 1.0 days to cover, ≈0.6% of shares.

  • TrendDOWNTREND

    17% below its 50-day average.

Who's buying

13F
Top holderSharesValue
Cresset Asset Management, LLC20,561$210.6K
JANE STREET GROUP, LLC15,463$158.4K
HRT FINANCIAL LP13,745$140.0K
CITADEL ADVISORS LLC10,000$102.5K
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO7$72.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jul 2026
12-month targets · 3 analysts

Price is below the lowest target. Median implies +254%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Jul 20, 2026Maxim Group
UPGRADE
UPGRADEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
AKTX Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Oct 15, 2026
Press release
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
CEO Abizer Gaslightwala discusses Akari’s novel PH1 payload strategy and execution priorities supporting AKTX-101’s advancement toward planned Phase…
Oct 13, 2026
Press release
Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
Mr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions…
Oct 1, 2026
Press release
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
Patent filing covers PH1 payload’s unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism
Aug 27, 2026
Company news
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Video webcast now available here
Aug 18, 2026
Press release
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models

Insider ledger

Form 4
$2.2K
bought · 1 insider
$0
sold · 0 insiders
DateInsiderTypeValue
Oct 14, 2026
Gaslightwala Abizer
CEO
EXERCISE$7.73
Oct 14, 2026
Gaslightwala Abizer
CEO
EXERCISE$3.09
Oct 14, 2026
Bazemore Robert B
Director
EXERCISE$0.31
Oct 14, 2026
Bazemore Robert B
Director
EXERCISE$1.24
Oct 14, 2026
Patel Sandip I
Director
EXERCISE$1.55
Oct 14, 2026
Patel Sandip I
Director
EXERCISE$2.47
Oct 12, 2026
Vat-Ho Vatnak
Chief Business Officer
AWARD87,000 sh
Oct 5, 2026
Bazemore Robert B
Director
AWARD$36.9K

Earnings setup

Estimates
Nov 11
reports in 16 days
−$2.38
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$2.38-$2.38–-$2.38—$0.00
Next Q-$2.11-$2.11–-$2.11—$0.00
Current FY-$9.05-$9.05–-$9.05—$0.00
Next FY-$8.65-$8.65–-$8.65—$0.00

Short side

FINRA· Sep 30, 2026
14,529
shares short
+35.0%
vs prior settlement
1.0
days to cover
≈0.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Other
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
CEO Abizer Gaslightwala discusses Akari’s novel PH1 payload strategy and execution priorities suppor
Oct 14, 2026 Insider
Gaslightwala Abizer acquired via exercise 19,333 shares
CEO @ $0.000400 ($7.73)
Oct 14, 2026 Insider
Gaslightwala Abizer acquired via exercise 7,733 shares
CEO @ $0.000400 ($3.09)
Oct 14, 2026 Insider
Bazemore Robert B acquired via exercise 773 shares
Director @ $0.000400 ($0.31)
Oct 1, 2026 SEC
Akari Therapeutics is holding a general meeting on October 28, 2026, to seek shareholder approval to increase the…
DEF 14A — Impact 4/10
Oct 1, 2026 SEC
Akari Therapeutics amended its CEO's employment agreement, increasing annual base salary from $475,000 to $625,000 and…
8-K — Impact 3/10
Aug 13, 2026 SEC
Akari Therapeutics reported Q2 2026 financial results, highlighting a net loss of $4.8M (vs. $1.9M in Q2 2025) as R&D…
8-K — Impact 5/10
May 28, 2026 Press
Akari Therapeutics announced CEO participation in a Virtual Investor interview discussing its first ASCO abstract…
Impact 4/10

SecBot reports

10 filings · 6 press releases · 1 bullish · 4 bearish · 5 neutral
All AKTX filing & press-release reports (16)